ÓXIDO DE GRAFENO E ÓXIDO DE GRAFENO REDUZIDO COMO ESTRATÉGIAS PARA O TRATAMENTO DA DOENÇA DE ALZHEIMER

• Ano de defesa: 2020
• Autor(a) principal: Schopf, Patricia Ferreira
• Orientador(a): Silva, Ivana Zanella da
• Banca de defesa: Andrade, Cinthia Melazzo de, Martins, Mirkos Ortiz
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso embargado
• Idioma: por
• Instituição de defesa: Universidade Franciscana
• Programa de Pós-Graduação: Programa de Pós-Graduação em Nanociências
• Departamento: Biociências e Nanomateriais
• País: Brasil
• Palavras-chave em Português: anticolinesterase, antioxidante, memória, nanotecnologia, tucumã.
• Palavras-chave em Inglês: anticholinesterase, antioxidant, memory, nanotechnology, tucuma.
• Área do conhecimento CNPq: ENGENHARIA/TECNOLOGIA/GESTÃO
• Link de acesso: http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/899

Alzheimer's disease is among the epidemic trends for the coming years in function of the increase in life expectancy of the population and the lack of effective treatment. Currently available treatments offer only a palliative approach for the disease. At the same time, graphene oxide and its reduced form are nanostructures that have gained prominence in the use of biological systems. In addition to having excellent biocompatibility coupled with low toxicity, reduced graphene oxide can cross the blood-brain barrier. This barrier is one of the main current challenges for the treatment of neurodegenerative problems, including Alzheimer's disease. In this context, the aim of this study was to investigate the action of graphene oxide, reduced graphene oxide and tucuma oil, isolated and combined, in the treatment of Alzheimer's disease through in silico, in vitro, in vivo and ex vivo methodologies. The theoretical results showed that the molecule that present the highest affinity for the proteins is that of reduced graphene oxide. This nanostructure interacted favorably with proteins -amyloid, acetylcholinesterase and N-methyl-D-aspartate receptor, however, interaction with the enzyme acetylcholinesterase occurred differently from the way current anticholinesterase drugs act. The results of the simulation of the first principles showed that, among the major components of tucuma oil, both nanostructures interact more strongly with 9, through physical adsorption. Furthermore, the experimental results revealed that the nanostructures, oil and their combinations were not toxic, both at the cellular and systemic level. Overall, all treatments had positive results against induced memory deficit, but reduced graphene oxide was more prominent as it was able to protect against memory deficit in all behavioral tests performed, having anticholinesterasic action, as predicted in theoretical studies, and antioxidant. Therefore, we can conclude that the reduced graphene oxide is, among the treatments studied, which has great therapeutic potential to be investigated in the treatment of Alzheimer's disease. However, further studies are needed to understand the mechanisms involved in the observed effects, and whether, in fact, this nanostructure acts to reverse the neuronal damage caused by the disease.